News Janssen's depression drug shows promise in phase 2 Ketamine may be best known as an anaesthetic illegally used as a party drug, but Janssen has shown that it could also be reformulated and used as a treatment for depression.
News Otsuka recruits Medibio to pinpoint mental health biomarkers Medibio's technology will be used to gather mental health biomarkers related to Otsuka's Abilify.
R&D SpringWorks spins out of Pfizer on rare disease mission A new biotech spun out of Pfizer is to develop four drugs for rare and serious diseases.
Views & Analysis Progress in mental health digital innovation What new digital technologies are being introduced to help reduce mental illness?
News Verily's Study Watch to feature in major PTSD trial Trial will enrol 5,000 people to determine causes of PTSD.
Views & Analysis Looking back, looking forward – Janssen’s 60 years on the ps... Improving targeted treatments and partnering on initiatives to reduce stigma and support mental health patients.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.